• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨质疏松症治疗与预防的成本效益——文献综述及参考模型

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.

作者信息

Zethraeus N, Borgström F, Ström O, Kanis J A, Jönsson B

机构信息

Centre for Health Economics, Stockholm School of Economics, P.O. Box 6501, S-113 83 Stockholm, Sweden.

出版信息

Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9.

DOI:10.1007/s00198-006-0257-0
PMID:17093892
Abstract

OBJECTIVE

The purpose of the paper is to update and review the latest developments related to modelling and economic evaluation of osteoporosis in the period 2002-2005 and further to present a reference model for the assessment of the cost-effectiveness of the prevention and treatment of osteoporosis.

DISCUSSION

The reference model is intended to be used for fracture specific interventions affecting the risk of fracture. An interface version and an extensive description of the model is available on the internet ( http://www.healtheconomics.se ) and also accessible via the International Osteoporosis Foundation ( http://www.osteofound.org ). The purpose of the reference model is to improve the quality and comparability of cost-effectiveness analysis in the osteoporosis field and to serve as a tool for validation of present and future cost-effectiveness models. The reference model allows the cost-effectiveness analysis to be carried out from a societal perspective including intervention, morbidity and mortality costs. The model has been extensively tested and calibrated, and meets the properties of good decision analytic modelling. The model is a state transition Markov cohort model, which is characterised by a 50-year time horizon divided into one year cycle lengths. The following health states are included: "healthy", "hip fracture", "spine fracture", "wrist fracture", "other fracture", and "dead".

CONCLUSION

The model is flexible and allows for the estimation of the cost-effectiveness over different ranges for a selected number of variables (e.g., age, fracture risk, cost of intervention).

摘要

目的

本文旨在更新和回顾2002 - 2005年期间与骨质疏松症建模和经济评估相关的最新进展,并进一步提出一个用于评估骨质疏松症预防和治疗成本效益的参考模型。

讨论

该参考模型旨在用于影响骨折风险的特定骨折干预措施。该模型的界面版本和详细描述可在互联网上获取(http://www.healtheconomics.se),也可通过国际骨质疏松症基金会获取(http://www.osteofound.org)。参考模型的目的是提高骨质疏松症领域成本效益分析的质量和可比性,并作为验证当前和未来成本效益模型的工具。该参考模型允许从社会角度进行成本效益分析,包括干预、发病率和死亡率成本。该模型已经过广泛测试和校准,符合良好决策分析建模的特性。该模型是一个状态转换马尔可夫队列模型,其特点是50年的时间跨度分为一年的周期长度。包括以下健康状态:“健康”、“髋部骨折”、“脊柱骨折”、“腕部骨折”、“其他骨折”和“死亡”。

结论

该模型具有灵活性,允许针对选定的一些变量(例如年龄、骨折风险、干预成本)在不同范围内估计成本效益。

相似文献

1
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.骨质疏松症治疗与预防的成本效益——文献综述及参考模型
Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9.
2
Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.改善腕部骨折后骨质疏松症护理质量干预措施的持续性、可重复性及成本效益:一项对照试验的结果
Osteoporos Int. 2007 Mar;18(3):261-70. doi: 10.1007/s00198-006-0248-1. Epub 2006 Nov 4.
3
Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.多方面干预措施提高腕部骨折后骨质疏松症护理质量的成本效益。
Osteoporos Int. 2011 Jun;22(6):1799-808. doi: 10.1007/s00198-010-1412-1. Epub 2010 Sep 29.
4
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.开发和验证用于骨质疏松症治疗经济评估的马尔可夫微模拟模型。
Value Health. 2009 Jul-Aug;12(5):687-96. doi: 10.1111/j.1524-4733.2008.00497.x.
5
Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model.骨质疏松症的筛查与治疗:状态转换微观模拟成本效益模型的构建与验证
Osteoporos Int. 2015 May;26(5):1477-89. doi: 10.1007/s00198-014-2999-4. Epub 2015 Jan 8.
6
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.地舒单抗:从瑞典支付方角度看,该药是骨质疏松老年男性患者的一种具有成本效益的选择。
Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002. Epub 2013 Nov 12.
7
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.三种推荐用于治疗骨质疏松症的药物的卫生经济学比较
Int J Clin Pharmacol Res. 2004;24(1):1-10.
8
Cost-effective osteoporosis treatment thresholds in Greece.希腊具有成本效益的骨质疏松症治疗阈值。
Osteoporos Int. 2015 Jul;26(7):1949-57. doi: 10.1007/s00198-015-3055-8. Epub 2015 Mar 5.
9
A health economic simulation model for the clinical management of osteoporosis.用于骨质疏松症临床管理的健康经济模拟模型。
Osteoporos Int. 2018 Mar;29(3):545-555. doi: 10.1007/s00198-017-4325-4. Epub 2017 Dec 1.
10
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.美国地诺单抗与口服双膦酸盐治疗绝经后骨质疏松症的成本效益
Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

引用本文的文献

1
Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.罗莫佐单抗治疗墨西哥骨折极高风险的重度绝经后骨质疏松症的成本效益分析。
PLoS One. 2025 Feb 7;20(2):e0299673. doi: 10.1371/journal.pone.0299673. eCollection 2025.
2
Exploring the potential cost-effectiveness and societal burden implications of screening for fracture risk in a UK general radiography setting.探索在英国普通放射检查环境中进行骨折风险筛查的潜在成本效益及对社会负担的影响。
BMC Musculoskelet Disord. 2025 Feb 4;26(1):112. doi: 10.1186/s12891-024-08202-6.
3
Generic Platform for the Multiplexed Targeted Electrochemical Detection of Osteoporosis-Associated Single Nucleotide Polymorphisms Using Recombinase Polymerase Solid-Phase Primer Elongation and Ferrocene-Modified Nucleoside Triphosphates.

本文引用的文献

1
Costs and quality of life associated with osteoporosis-related fractures in Sweden.瑞典与骨质疏松性骨折相关的成本和生活质量
Osteoporos Int. 2006;17(5):637-50. doi: 10.1007/s00198-005-0015-8. Epub 2005 Nov 9.
2
Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial.瑞典激素替代疗法成本效益的重新评估:基于女性健康倡议随机对照试验的结果
Int J Technol Assess Health Care. 2005 Fall;21(4):433-41. doi: 10.1017/S0266462305050609.
3
The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study.
基于重组酶聚合酶固相引物延伸和二茂铁修饰三磷酸核苷的骨质疏松相关单核苷酸多态性多重靶向电化学检测通用平台
ACS Cent Sci. 2023 Jul 19;9(8):1591-1602. doi: 10.1021/acscentsci.3c00243. eCollection 2023 Aug 23.
4
Predictive factors for conversion from conservatively to surgically treatment osteoporotic thoracolumbar compression fractures based on sagittal parameters and magnetic resonance imaging features.基于矢状参数和磁共振成像特征预测保守治疗向手术治疗骨质疏松性胸腰椎压缩性骨折的转换因素。
Eur Spine J. 2023 Nov;32(11):3933-3940. doi: 10.1007/s00586-023-07864-5. Epub 2023 Jul 26.
5
Feasibility Analysis of the Bone Cement-Gelatine Sponge Composite Intravertebral Prefilling Technique for Reducing Bone Cement Leakage in Stage I and II Kümmell's Disease: A Prospective Randomized Controlled Trial.一期和二期 Kümmell 病中采用骨水泥-明胶海绵复合材料进行椎体内预填充技术减少骨水泥渗漏的可行性分析:一项前瞻性随机对照试验。
Orthop Surg. 2023 Jul;15(7):1763-1771. doi: 10.1111/os.13764. Epub 2023 May 30.
6
The influence of osteoporotic vertebral fractures on global sagittal alignment in elderly patients: a systematic review and meta-analysis.老年骨质疏松性椎体骨折患者矢状位平衡的影响:系统评价和荟萃分析。
Eur Spine J. 2023 Jul;32(7):2580-2587. doi: 10.1007/s00586-023-07780-8. Epub 2023 May 24.
7
Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia.地舒单抗治疗马来西亚绝经后骨质疏松症的成本效益分析。
Osteoporos Int. 2022 Sep;33(9):1909-1923. doi: 10.1007/s00198-022-06444-5. Epub 2022 May 31.
8
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.在加拿大,使用罗莫佐单抗治疗绝经后骨折高危女性的成本效益分析。
Arch Osteoporos. 2022 Apr 26;17(1):71. doi: 10.1007/s11657-022-01106-9.
9
Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.乳腺癌和卵巢癌基因筛查与治疗策略成本效用分析中的效用数据。
Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
10
Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer.一项随机、多中心、试点试验的可行性结果,该试验比较了早期乳腺癌患者辅助唑来膦酸标准每6个月给药一次与单次给药的效果。
J Bone Oncol. 2020 Dec 13;26:100343. doi: 10.1016/j.jbo.2020.100343. eCollection 2021 Feb.
骨密度测量对骨折风险的长期预测价值与测量部位及诊断时的年龄无关:前瞻性流行病学危险因素研究结果
Osteoporos Int. 2006;17(3):471-7. doi: 10.1007/s00198-005-0009-6. Epub 2005 Oct 28.
4
Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women.甲状旁腺激素(PTH)治疗绝经后妇女骨质疏松症的经济学评价。
Osteoporos Int. 2006 Feb;17(2):201-11. doi: 10.1007/s00198-005-1959-4. Epub 2005 Jul 19.
5
Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials.髋部保护器能否降低机构养老和社区居家老年人髋部骨折的风险?一项随机对照试验的系统评价和荟萃分析。
Osteoporos Int. 2005 Dec;16(12):1461-74. doi: 10.1007/s00198-005-1932-2. Epub 2005 Jul 1.
6
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.骨质疏松症预防和治疗干预措施的经济学评估:文献的结构化综述
Osteoporos Int. 2006 Jan;17(1):29-40. doi: 10.1007/s00198-005-1943-z. Epub 2005 Jun 25.
7
Predictive value of BMD for hip and other fractures.骨密度对髋部及其他骨折的预测价值。
J Bone Miner Res. 2005 Jul;20(7):1185-94. doi: 10.1359/JBMR.050304. Epub 2005 Mar 7.
8
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.阿仑膦酸盐、依替膦酸盐、利塞膦酸盐、雷洛昔芬和特立帕肽用于预防和治疗绝经后骨质疏松症的系统评价与经济学评估
Health Technol Assess. 2005 Jun;9(22):1-160. doi: 10.3310/hta9220.
9
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.阿仑膦酸盐治疗骨质减少的绝经后女性的成本效益。
Ann Intern Med. 2005 May 3;142(9):734-41. doi: 10.7326/0003-4819-142-9-200505030-00008.
10
Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.阿仑膦酸钠预防丹麦女性骨质疏松性骨折的成本效益分析
Basic Clin Pharmacol Toxicol. 2005 May;96(5):387-96. doi: 10.1111/j.1742-7843.2005.pto_08.x.